AREXVY Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted
Highlights:
For individuals aged 60 or above:
- Overall effectiveness in protecting against lower respiratory tract disease (LRTD) caused by RSV - 82.6%
- Efficacy in protection against RSV LRTD in patients with at least 1 comorbidity of interest* - 94.6%
*Comorbidities of interest: COPD, asthma, any chronic respiratory/pulmonary disease, chronic heart failure, diabetes mellitus, advanced liver or renal disease
How:
- Intramuscular Injection
- Single-dose administration
Designated Quality HealthCare Medical Centres:
Click here for more details.
Scan & Book appointment via QHMS mobile app or WhatsApp 8301-8301
Recommended for
Individuals aged 60 or above